

# Pro-inflammatory cytokine response and genetic diversity in merozoite surface protein 2 of *Plasmodium falciparum* isolates from Nigeria

Olusola Ajibaye<sup>1,2</sup>, Akinniyi A Osuntoki<sup>2</sup>, Albert OT Ebuehi<sup>2</sup>, Bamidele A Iwalokun<sup>1</sup>, Emmanuel O Balogun<sup>3,4</sup>, Kathleen N Egbuna<sup>1</sup>

<sup>1</sup>Biochemistry and Nutrition Division, Nigerian Institute of Medical Research, <sup>2</sup>Department of Biochemistry, College of Medicine, University of Lagos, Lagos, <sup>4</sup>Department of Biochemistry, Ahmadu Bello University, Zaria 2222, Nigeria, <sup>3</sup>Department of Biomedical Chemistry, Graduate School of Medicine, University of Tokyo, Tokyo 113-0033, Japan

## Abstract

**Background:** Polymorphisms in *Plasmodium falciparum* merozoite surface protein-2 (*msp-2*) and associated parasite genetic diversity which varies between malaria-endemic regions remain a limitation in malaria vaccine development. Pro-inflammatory cytokines are important in immunity against malaria, understanding the influence of genetic diversity on cytokine response is important for effective vaccine design.

**Materials and Methods:** *P. falciparum* isolates obtained from 300 Nigerians with uncomplicated falciparum malaria at Ijede General Hospital, Ijede (IJE), General Hospital Ajeromi, Ajeromi (AJE) and Saint Kizito Mission Hospital, Lekki, were genotyped by nested polymerase chain reaction of *msp-2* block 3 while ELISA was used to determine the pro-inflammatory cytokine response to describe the genetic diversity of *P. falciparum*.

**Results:** Eighteen alleles were observed for *msp-2* loci. Of the 195 isolates, 61 (31.0%) had only FC27-type alleles, 38 (19.7%) had only 3D7-type alleles, and 49.3% had multiple parasite lines with both alleles. Band sizes were 275–625 bp for FC27 and 150–425 bp for 3D7. Four alleles were observed from LEK, 2 (375–425 bp) and 2 (275–325 bp) of FC27-and 3D7-types, respectively; 12 alleles from AJE, 9 (275–625 bp) and 3 (325–425 bp) of FC27-types and 3D7-types, respectively; while IJE had a total of 12 alleles, 9 (275–625 bp) and 3 (325–425 bp) of FC27-types and 3D7-types, respectively. Mean multiplicity of infection (MOI) was 1.54. Heterozygosity ( $H_e$ ) ranged from 0.77 to 0.87 and was highest for IJE (0.87). Cytokine response was higher among <5 years and was significantly associated with MOI ( $P > 0.05$ ) but with neither parasite density nor infection type.

**Conclusion:** *P. falciparum* genetic diversity is extensive in Nigeria, protection via pro-inflammatory cytokines have little or no interplay with infection multiplicity.

**Key Words:** Cytokemia, falciparum malaria, multiplicity of infection, polymorphism, pro-inflammatory cytokine

## Address for correspondence:

Mr. Olusola Ajibaye, Biochemistry and Nutrition Division, Nigerian Institute of Medical Research, Lagos, Nigeria. E-mail: [sajibaye@yahoo.com](mailto:sajibaye@yahoo.com)

Received: 22.12.2015, Accepted: 20.08.2016

## Access this article online

### Quick Response Code:



### Website:

[www.advbiores.net](http://www.advbiores.net)

### DOI:

10.4103/2277-9175.192631

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

**For reprints contact:** [reprints@medknow.com](mailto:reprints@medknow.com)

**How to cite this article:** Ajibaye O, Osuntoki AA, Ebuehi AO, Iwalokun BA, Balogun EO, Egbuna KN. Pro-inflammatory cytokine response and genetic diversity in merozoite surface protein 2 of *Plasmodium falciparum* isolates from Nigeria. Adv Biomed Res 0;0:0.

## INTRODUCTION

Apicomplexan parasites constitute one of the most important groups of human and animal pathogens, none more so than the malaria parasites, which cause devastating death and disease globally.<sup>[1]</sup> Malaria, an important protozoan parasitic disease in Nigeria, is caused by *Plasmodium* parasites transmitted to man through the bite of infected female *Anopheles* mosquitoes during blood meal. Due to a limited number of drugs available for treatment of *Plasmodium falciparum* malaria as a result of the spread of multi-drug resistance strains of the parasites, the only reliable intervention, malaria vaccine also faces huge limitations posed by genetic diversity of the parasite.

Molecular studies have demonstrated that individuals living in endemic areas generally harbor multiple *P. falciparum* strains that are genetically distinct and play an important role in the development of strain-specific immunity.<sup>[2-4]</sup> Such individuals, however, may develop immunity to infection from some but not all the strains to which they are exposed. The multiplicity of infection (MOI) which is an epidemiological measure refers to the number of different parasite genotypes co-infecting a single host also reported as an indicator of immune status and transmission intensity.<sup>[5]</sup>

Merozoite surface proteins (*msp*) of *P. falciparum* are essential parasite antigens involved in erythrocyte invasion affecting parasite density and eventually severe pathology of which *msp-2* is a good candidate for inclusion into a malaria vaccine. As part of immune evasion mechanism, *msp-2* DNA sequences include variable block 3 which generates antigenically diverse forms that can be used to distinguish by size the different alleles after polymerase chain reaction (PCR) amplification.<sup>[6,7]</sup> This gene is represented as a single copy on *P. falciparum* genome, and a high degree of polymorphism has been reported in the central variable region for *msp-2* gene.<sup>[6]</sup> Typing of this polymorphic *P. falciparum* genome region has permitted the determination of malaria infection indicators, e.g. diversity of *P. falciparum* strains and MOI, which contribute to the description of malaria situation in a given location. Genotyping of the *msp-2* gene, therefore, is a standard method for assessing MOI in *P. falciparum* studies, as it is highly polymorphic in length and sequence.<sup>[8]</sup>

The human immune system comprises a complex network of specialized cells and organs that function in harmony to achieve protection against foreign invaders. Acquired immunity to malaria involves

both antibody-mediated and cell-mediated immunity. Naturally acquired immunity to malaria takes as long as 10–15 years of exposure to develop, it is nonsterile and is species-, stage-, strain-, and variant-specific for which residents in malaria endemic areas frequently have premunition (parasitemia and antibodies without symptoms).<sup>[9]</sup> Lymphocytes play a central role in the regulation of both cell-mediated and antibody-mediated responses against different antigens. It is well established that B cells and antibodies play a major role in immunity to malaria however; it is now evident that T cells mediate the acquisition and maintenance of protective immune responses to malaria infection.<sup>[10]</sup>

Cytokines play both protective and pathological roles in malaria, however, early and effective inflammatory response is crucial in the control of parasitemia and resolution of malaria infection through the mechanism of tumor necrosis factor alpha (TNF- $\alpha$ ).<sup>[11]</sup> TNF- $\alpha$ , interleukin-1 $\beta$  (IL-1 $\beta$ ), and IL-12 are pro-inflammatory cytokines which are mediators of inflammation but crucial in malaria immunity.<sup>[12]</sup> IL-12 is an immunoregulatory molecule which stimulates endogenous interferon- $\gamma$  production by T lymphocytes and natural killer cells thereby increasing parasites clearance but with improved erythropoiesis.<sup>[13]</sup> IL-1 $\beta$  is an endogenous pyrogen that plays a significant role in protection against malaria as does TNF- $\alpha$ .<sup>[14]</sup> MOI which is an indicator of the malaria transmission in a given location is a function of parasite allelic variation suggesting a possible relationship between MOI and cytokine response.

The influence of *P. falciparum* genetic diversity and MOI on immunity against malaria has been reported; however, the relationship between the varying multiplicity of *P. falciparum* infections on innate immune response, especially pro-inflammatory cytokines in malaria has not yet been fully understood. We studied the diversity of *P. falciparum* isolates from Nigeria to determine MOI and its relationship with pro-inflammatory cytokine response.

## METHODS


### Study design and sites

In this cross-sectional study, participants were recruited at the peak of malaria transmission (i.e. March–September) 2013 at three health facilities in Lagos State, South–Western Nigeria, namely: (a) Ijede General Hospital, Ijede (IJE), a secondary public health care facility; (b) Ajeromi General Hospital, Ajegunle, a secondary public health care facility; (c) St. Kizito Primary Healthcare Centre, Lekki, a not for-profit primary healthcare facility [Figure 1].

Malaria transmission is high in these areas while the selected facilities have above 500 outpatients a week. After obtaining informed consent (parental consent and/or assent from under-16 participants), patients presenting at these sites with symptoms suggestive of malaria, (axillary temperature  $\geq 37.5$  or history of fever in the last 48 h) with *P. falciparum* mono-infection (a minimum of 5000 *P. falciparum* parasites/ $\mu\text{L}$  estimated by thick film examination) who consented were enrolled into the study after they were treated with artemether-lumefantrine (20–120 mg) according to national policies (FMoH, 2005). Laboratory investigations were done at the Malaria Research Laboratory (Biochemistry and Nutrition Division), Public Health Division (TDR Laboratory) and Microbiology Division (Immunology Laboratory) of the Nigerian Institute of Medical Research, Lagos.

### Ethical approval

Approval was obtained from the Nigerian Institute of Medical research (NIMR) Institutional Ethics Review Board (IRB) for clearance to carry out the research.



**Figure 1:** Map showing location of the three study sites in Lagos Nigeria ● = The health facility used for study, located in the different local government areas in Lagos Nigeria; □ = Other local government areas in Lagos state; ■ = Ibeju-Lekki local government area; ■ = Ajeromi local government area; ■ = Ikorodu local government area, Lagos, Nigeria

### Parasitemia assessment

Finger-pricked blood samples were collected from each participant. Slides were prepared according to WHO standard protocol, Giemsa stained and independently read by two microscopists for the estimation of parasite densities and species in the thick blood films, assuming an average white-blood-cell count of 8000/ $\mu\text{L}$ . Venous blood samples of positive participants were collected into plain bottles for ELISA.

### Evaluation of cytokine response

Levels of TNF- $\alpha$ , IL-12, and IL-1 $\beta$  were assessed in sera of included participants using antigen capture ELISA.<sup>[15]</sup>

### Malaria parasite DNA extraction from dried blood spots and polymerase chain reaction amplification

Extraction of genomic DNA was carried out using QIAGEN QIAamp<sup>®</sup> DNA Extraction Mini-kit (Qiagen, UK, cat no: 51306) from the individual dried blood spots. The extracted DNA samples were stored at  $-20^{\circ}\text{C}$  until PCR. The quality as well as quantity of each DNA sample was determined using Nanodrop 1000 (Thermo Fisher Scientific, USA). The oligonucleotide primers were designed from published sequences as listed in the Nucleotide Blast Database, to amplify block 3 of *m*sp-2. The genes were amplified by nested PCR in which DNA regions were amplified in 50  $\mu\text{L}$  reaction mixtures containing: 1.25U BioTaq<sup>™</sup> DNA polymerase (Bioline, London, UK), 1 $\times$  Taq polymerase reaction buffer, 2.5 mM  $\text{MgCl}_2$ , 0.25 mM dNTPs, and 1  $\mu\text{M}$  of each primer. The following thermocycling profile was used for the primer sets: An initial denaturation step at  $95^{\circ}\text{C}$  for 5 min, followed by thirty cycles consisting of 1 min of denaturation step at  $94^{\circ}\text{C}$ , 2 min of annealing at  $55^{\circ}\text{C}$ , and 2 min of extension at  $72^{\circ}\text{C}$  followed by a final extension at  $72^{\circ}\text{C}$  for 5 min. The same cycling conditions were used for the secondary PCR (Nest 2) reaction except that the extension in the cycle was for 1 min. Each amplification with conserved or family-specific primer pair [Table 1], being done separately as described.<sup>[16]</sup> PCR products were electrophoresed on 1.2% Agarose gels using  $0.5 \times \text{TBE}$  buffer at 100 V, and DNA bands visualized with the gel documentation system (Infinity

**Table 1:** Sequences of oligonucleotide primers used to amplify merozoite surface protein 2 polymorphic regions of *Plasmodium falciparum* isolates from Nigeria

Gene	Primer	Sequence	Notes
<i>Msp-2</i>	<i>Msp-2</i> -OF	5'-ATGAAGGTAATTAACATTGTCTATTATA-3'	Conserved
	<i>Msp-2</i> -OR	5'-CTTTGTTACCATCGGTACATTCCT-3'	Conserved
	FC27-OF	5-AATACTAAGAGTGTAGGTGCARATGCTCCA -3'	FC27 family-specific
	FC27-OR	5'-TTTTATTGGTGCATTGCCAGAACTTGAAC-3'	FC27 family-specific
	IC/3D7-F	5'-AGAAGTATGGCAGAAAGTAAKCCCTYCTACT-3'	3D7 family-specific
	IC/3D7-R	5'GATTGTAATTCGGGGGATTCAGTTTGTTCG-3'	3D7 family-specific

3026, Vilber Lourmat, Marnela Valled, France) after ethidium bromide staining. The sizes of the fragments obtained were estimated by comparison to the 1.3 kb (100 bp) DNA ladder (Jena Bioscience GmbH, Germany) as marker in comparison with standard purified genomic DNA from 3D7 laboratory strains similarly electrophoresed.

### Detection of alleles


The PCR products were visualized by ultraviolet transillumination on gel documentation system [Plates 1 and 2]. Alleles in each family were considered the same if fragment sizes were within 2 bp interval.<sup>[17]</sup>

### Data analysis

The MOI, or number of genotypes per infection, was determined by dividing the total number of fragments detected by the number of samples positive for the same marker. Samples possessing only one genotype per family were considered monoclonal while those with multiple genotypes were described as polyclonal. Relationships were studied using Spearman correlation test. The prevalence of each family was calculated as the percentage of samples containing allele(s) of this family. The distribution of the specific families was estimated at each of the loci as the percentage of fragments assigned to one family within the overall number of fragments. Analysis was done with SPSS (version 20) (Armonk, NY: IBM Corp) software. As a measure of genetic diversity, the expected heterozygosity ( $H_E$ ) which represents the probability of being infected by two parasites with different alleles at a given locus and ranging between 0 and 1 was calculated by use of the formula:

$$H_E = (n/[n - 1]) [(1 - \sum P_i^2)], \text{ where } n = \text{sample size, } P_i = \text{allele frequency.}$$

$H_E$  estimates the fraction of all parasites that would be heterozygous for *m*sp-2 loci.



**Plate 1:** Agarose gel photograph of merozoite surface protein-2 (FC27 family) resolved on 1.2% gel. Examples of clonal differentiation of *Plasmodium falciparum* showing different band sizes of FC27 family from parasite lines elucidated by the 100 bp DNA ladder and 3D7 positive internal control. Lanes 1–4 had single allele, 5–8 were negative for FC27 while 9 and 12 had two alleles but Lane 14 shows the negative control

The MOI was determined by dividing the total number of fragments detected by the number of samples positive for the same marker. Samples possessing only one genotype per family were considered monoclonal while those with multiple genotypes were described as polyclonal.


$$\text{MOI} = \frac{\text{Total number of fragments (genotypes)}}{\text{Number of samples positive for the marker}}$$

## RESULTS

From the three sites, 1883 patients were screened, 300 (100 per site) out of the 384 *P. falciparum* positive patients were included having met the inclusion criteria. The median age was 10 years while 60 (20%) were <5 years with significantly higher geometric mean parasite density (GMPD)  $136,267 \pm 1,449$  parasites/ $\mu$ L ( $P < 0.05$ ) compared to 240 (80%)  $\geq 5$  years with GMPD  $32,912 \pm 1,256$  parasites/ $\mu$ L. Malaria prevalence was observed to be 20.39% while 155 (51.67%) participants were male and 145 (48.33%) female.

### Genetic diversity and allelic frequency

Nested PCR on *m*sp-2 confirmed samples revealed that both 3D7 and FC27 allele classes of *P. falciparum m*sp-2 were present in the study sites. Of the 300 isolates, only 195 were PCR positive for *m*sp-2. Eighteen different alleles were observed for *m*sp-2 locus, FC27 family being more polymorphic. Analysis showed that 61 (31.0%) had only FC27-type alleles, 38 (19.7%) had only 3D7-type alleles, and 96 (49.3%) had multiple parasite lines with both alleles. Of the total 330 fragments, 145 (43.9%) and 185 (56.1%) belonged to 3D7 and FC27 alleles, respectively [Table 2]. The band sizes were 275–625 bp for FC27 and 150–425 bp for 3D7. Four alleles were observed from LEK, 2 (375–425 bp) and 2 (275–325 bp) of FC27-types and 3D7-types, respectively; 12 alleles from



**Plate 2:** Agarose gel photograph of merozoite surface protein-2 3D7 family resolved on 1.2% gel. Examples of clonal differentiation of *Plasmodium falciparum* showing different band sizes of 3D7 family from parasite lines elucidated by the 100 bp DNA ladder and 3D7 positive internal control

Ajeromi (AJE), 9 (275–625 bp) and 3 (325–425 bp) of FC27-types and 3D7-types, respectively, while IJE had a total of 12 alleles 9 (275–625 bp) and 3 (325–425 bp) of FC27-types and 3D7-types, respectively [Table 3]. The three sites recorded relatively high expected  $H_E$  values (0.77–0.87) which were highest for IJE (0.87).

### Multiplicity of *Plasmodium falciparum* infection

Mean MOI was 1.54, while in IJE, Lekki and AJE the MOI was 2.12, 0.86 and 1.33, respectively. MOI was significantly higher in IJE  $P < 0.05$  [Table 3].


### Evaluation of cytokine response

IL-1 $\beta$  and IL-12 were significantly higher among participants below 5 years than those  $\geq 5$  years [Table 4]. MOI was found to be strongly positively correlated with age ( $r = 0.79, P = 0.003$ ). There was no significant correlation between MOI and any of Sex, IL-12, IL-1 $\beta$ , TNF- $\alpha$  or type of disease ( $P > 0.05$ ) Table 5. TNF- $\alpha$  response was highest among participants from LEK [Figures 2 and 3].

## DISCUSSION

This study investigated the polymorphism of *P. falciparum* sub-population in Nigeria by nested-PCR typing. The method may not allow differentiation of alleles identical in size but differing in sequence.<sup>[17]</sup> Acquired immunity to malaria develops as a result of exposure to diverse *P. falciparum* strains in malaria endemic areas. Increase in the knowledge of the genetic diversity of *P. falciparum* is required to improve understanding of the pathological mechanisms of malaria, the processes of acquired immunity, the spread and genetic background of drug resistance, and transmission conditions.

MOI and parasite genetic diversity are indicators of malaria infection with significant consideration for place and time in relation to immunity including



**Figure 2:** Levels of tumor necrosis factor- $\alpha$ , interleukin-1 $\beta$  and interleukin-12 of participants from the three study sites. ● = Ijeda General Hospital Ijeda, Lagos, Nigeria; ● = St. Kizito Primary Healthcare Centre, Lekki, Lagos, Nigeria; ● = Ajeromi General Hospital, Ajegunle, Lagos, Nigeria

innate T-Cell immunity in malaria. Contrary to reports by Oyedeji *et al.*<sup>[18]</sup> from the northern region of Nigeria and Aubouy *et al.*<sup>[7]</sup> from Gabon, our study found higher proportions of FC27-type alleles of *m*sp-2 than the 3D7-type which was consistent with findings by Kiwuwa *et al.*<sup>[19]</sup> from their study in Uganda. These clearly underscore the significance of spatial dynamics in *P. falciparum* genetic diversity. Over all Mean MOI was low compared to what was reported by Amodu *et al.*<sup>[21]</sup> and Ojurongbe *et al.*<sup>[22]</sup> This could be expected in view of the myriad of intervention and control measures that must have played a significant role in curbing malaria transmission regardless of seasonality

**Table 2: Distribution of merozoite surface protein 2 alleles in isolates from the sites studied**

<i>Msp-2</i> family	n (%)	
	Isolates	Fragments
3D7 (only)	38 (19.7)	145 (43.9)
FC27 (only)	61 (31.0)	185 (56.1)
FC27 + 3D7	96 (49.3)	330 (100)

*Msp-2*: Merozoite surface protein 2

**Table 3: Merozoite surface protein 2 polymorphism in isolates from 195 Nigerians presenting with *Plasmodium falciparum* malaria**

Marker family	Ijeda	Lekki	Ajeromi
<i>Msp-2</i>			
3D7/ICI			
Number of distinct bands	3	2	3
Number of samples with corresponding alleles (%)	63 (96.92)	33 (50.77)	24 (36.92)
Percentage of fragments with corresponding alleles	53.70	40.74	35.0
Size range (bp)	150-325	375-425	325-425
FC27			
Number of distinct bands	9	2	9
Number of samples with corresponding alleles (%)	55 (84.62)	28 (43.08)	42 (64.62)
Percentage of fragments with corresponding alleles	46.3	59.25	65.0
Size range (bp)	375-550	375-425	275-625
MOI*95% CI	2.12	0.86	1.33

Fragments of *Plasmodium falciparum msp-2* established by family (FC27 or 3D7), \*MOI=Multiplicity of infection. Over all MOI=1.54. CI: Confidence interval, *m*sp-2: Merozoite surface protein 2

**Table 4: Relationship multiplicity of infection with age, sex, cytokines and type of malaria**


Parameter	r, P
Age	0.79, 0.03
Sex	0.11, 0.57
TNF- $\alpha$	0.44, 0.12
IL-12	0.57, 0.67
IL-1 $\beta$	0.8, >0.05
Type (symptomatic/asymptomatic)	0.8, 0.42

Participant age (years) was significantly correlated (Spearman's correlation) with MOI. MOI: Multiplicity of infection, TNF- $\alpha$ : Tumor necrosis factor alpha, IL: Interleukin

**Table 5: Relationship of merozoite surface protein 2 polymorphisms with pro-inflammatory cytokines**

Marker	Number of <i>m</i> sp-2 genotypes			
	0	1	2	3
<b>3D7</b>				
TNF- $\alpha$ (mean $\pm$ SEM) (ng/L)	206.8 $\pm$ 38.91 <sup>d</sup>	255.8 $\pm$ 28.82	380.0 $\pm$ 68.19	-
IL-12 (mean $\pm$ SEM)	110.0 $\pm$ 58.3 <sup>b</sup>	90.0 $\pm$ 27.93	80.0 $\pm$ 3.16 <sup>d</sup>	-
IL-1 $\beta$ (mean $\pm$ SEM)	39.0 $\pm$ 8.0	25.25 $\pm$ 5.85	15.00 $\pm$ 1.89	-
<b>FC27</b>				
TNF- $\alpha$ (mean $\pm$ SEM) (ng/L)	180.0 $\pm$ 42.47	170.0 $\pm$ 27.10	262.40 $\pm$ 27.17	287.9 $\pm$ 7.1
IL-12 (mean $\pm$ SEM)	212.0 $\pm$ 49.51	149.10 $\pm$ 37.21	90.0 $\pm$ 24.87	90.00 $\pm$ 30.61
IL-1 $\beta$ (mean $\pm$ SEM)	59.25 $\pm$ 11.55	36.10 $\pm$ 12	43.16 $\pm$ 5.27	25.79 $\pm$ 7.71
<b>3D7 + Fc27</b>				
TNF- $\alpha$ (mean $\pm$ SEM) (ng/L)	-	175.40 $\pm$ 26.5 <sup>e</sup>	316.4 $\pm$ 41 <sup>e</sup>	291.73 $\pm$ 74.63
IL-12 (mean $\pm$ SEM)	-	120 $\pm$ 45.61	90.0 $\pm$ 27.93	85.0 $\pm$ 3.33
IL-1 $\beta$ (mean $\pm$ SEM)	-	43.50 $\pm$ 7.1 <sup>a,b</sup>	20.0 $\pm$ 5.3 <sup>a</sup>	15.0 $\pm$ 2.64 <sup>b</sup>

<sup>a, b, c, d</sup>P<0.05: ANOVA and Tukey (for parametric); Kruskal-Wallis and Dunn's multiple comparison (for nonparametric). TNF- $\alpha$ : Tumor necrosis factor alpha, SEM: Standard error of mean, IL: Interleukin, *m*sp-2: Merozoite surface protein 2



**Figure 3:** Distribution of merozoite surface protein-2 families during the cross-sectional sample collection at the three sites. ■ : 3D7: One of the two allelic families of *Plasmodium falciparum* merozoite surface protein-2; ■ : FC27: The second allelic family of *Plasmodium falciparum* merozoite surface protein-2

and intensity of infection. MOI was observed for the first time in Ajegunle area of Lagos state to be 1.33 for which IJE community had the highest MOI (2.12) among the three study sites. IJE is the most remote setting of the sites studied with higher proportions of the dwellers being of low socioeconomic status; majorly farmers and low-level civil servants. Malaria transmission is highest in IJE and lowest in LEK as deduced from the MOIs. In all the sites, there was a predominance of FC27 alleles consistent with reports from previous investigations in Nigeria,<sup>[23]</sup> but contrary to reports from Oceania, Barry *et al.*,<sup>[24]</sup> and Mohammed *et al.*<sup>[25]</sup> This identified the importance of determination of *P. falciparum* genetic diversity in control, elimination and in vaccine design which has been shown to be strongly related with distance and population differentiation.<sup>[24]</sup>

The genetic diversity of a parasite population is shaped by various influences, including genetic drift, mutation,

natural selection, and gene flow. *Msp-2* is the second most abundant protein on the surface of the merozoite and a target of naturally acquired antibodies, and therefore diversity is influenced by immune (balancing) selection.<sup>[26-28]</sup> Expected  $H_E$  was found to be high with a narrow range in the three populations studied connoting diverse genetic structure of *P. falciparum* in these populations taken together. One explanation for the high levels of diversity in all the populations studied is that parasite populations in the region are panmictic. This study also revealed that there was no dependence of genetic diversity or number of genotypes of *P. falciparum* on the T-cell response and invariably innate immune responses regardless of their involvement in establishing natural immunity against malaria. IL-12, IL-1 $\beta$ , and TNF- $\alpha$  were not significantly correlated with number of genotypes of *P. falciparum* although IL-1 $\beta$  was significantly correlated with the number of 3D7 alleles of *m*sp-2. Findings reported here suggest that the diversity of *P. falciparum* parasite populations and therefore the resilience to antimalarial interventions will remain high unless the MOI can be significantly reduced. A robust understanding and management of the relationship between immune response, MOI, and genetic diversity is needed in the context of actualizing malaria control in Nigeria. High levels of diversity indicate a malaria population with a greater capacity to evade interventions and thus more difficult to control. Findings from this study will be important in implementing malaria control strategies in the country, as elimination may influence genetic diversity and the resultant heterozygosity of the parasite in Nigeria

### CONCLUSION

The results of this study showed genetic diversity and allelic distribution in *m*sp-2 in *P. falciparum* isolates

from Lagos, Nigeria. MOI could be instrumental in the evaluation of intervention against malaria, especially involving innate immune responses. However, this needs further studies in several parts of the country, to examine the spatial/periodic changes in the genetic diversity of *P. falciparum* in Nigeria.

### Acknowledgments

Authors are grateful to the patients who contributed samples for this study, and to the staff, nurses, and doctors of the hospitals visited who facilitated sample collection and the Microbiology Division of the Nigerian Institute of Medical Research, Nigeria, for their support.

### Financial support and sponsorship

Nil.

### Conflicts of interest

There are no conflicts of interest.

### REFERENCES

- Baum J, Chen L, Healer J, Lopatnicki S, Boyle M, Triglia T, *et al.* Reticulocyte-binding protein homologue 5 – An essential adhesin involved in invasion of human erythrocytes by *Plasmodium falciparum*. *Int J Parasitol* 2009;39:371-80.
- Kyabayinze DJ, Karamagi C, Kiggundu M, Kanya MR, Wabwire-Mangen F, Kironde F, *et al.* Multiplicity of *Plasmodium falciparum* infection predicts antimalarial treatment outcome in Ugandan children. *Afr Health Sci* 2008;8:200-5.
- Takala SL, Escalante AA, Branch OH, Kariuki S, Biswas S, Chaiyaroj SC, *et al.* Genetic diversity in the block 2 region of the merozoite surface protein 1 (MSP-1) of *Plasmodium falciparum*: Additional complexity and selection and convergence in fragment size polymorphism. *Infect Genet Evol* 2006;6:417-24.
- Ferreira MU, Hartl DL. *Plasmodium falciparum*: Worldwide sequence diversity and evolution of the malaria vaccine candidate merozoite surface protein-2 (MSP-2). *Exp Parasitol* 2007;115:32-40.
- Assefa SA, Preston MD, Campino S, Ocholla H, Sutherland CJ, Clark TG. estMOI: Estimating multiplicity of infection using parasite deep sequencing data. *Bioinformatics* 2014;30:1292-4.
- Ibara-Okabande R, Koukoulakia-Koussounda F, Ndounga M, Vouvongui J, Malonga V, Casimiro PN, Ibara JR, Sidibe A, and Ntoumi F. Reduction of multiplicity of infections but no change in msp2 genetic diversity in *Plasmodium falciparum* isolates from Congolese children after introduction of artemisinin-combination therapy. *Malar J* 2012;11:410.
- Aubouy A, Migot-Nabias F, Deloron P. Polymorphism in two merozoite surface proteins of *Plasmodium falciparum* isolates from Gabon. *Malar J* 2003;2:12.
- Ntoumi F, Contamin H, Rogier C, Bonnefoy S, Trape JF, Mercereau-Pujjalon O. Age-dependent carriage of multiple *Plasmodium falciparum* merozoite surface antigen-2 alleles in asymptomatic malaria infections. *Am J Trop Med Hyg* 1995;52:81-8.
- Farouk SE, Dolo A, Bereczky S, Kouriba B, Maiga B, Farnet A, *et al.* Different antibody- and cytokine mediated responses to *Plasmodium falciparum* parasite in two sympatric ethnic tribes living in Mali. *Microbes and Infection* 2005;7:110-7.
- Moncunill G, Mayor A, Jiménez A, Nhabomba A, Puyol L, Manaca MN, *et al.* Cytokine and antibody responses to *Plasmodium falciparum* in naïve individuals during a first malaria episode: Effect of age and malaria exposure. *PLoS One* 2013;8:e55756.
- Wroczyńska A, Nahorski W, Bakowska A, Pietkiewicz H. Cytokines and clinical manifestations of malaria in adults with severe and uncomplicated disease. *Int Marit Health* 2005;56:103-14.
- Fillol F, Sarr JB, Boulanger D, Cisse B, Sokhna C, Riveau G, *et al.* Impact of child malnutrition on the specific anti-*Plasmodium falciparum* antibody response. *Malar J* 2009;8:116.
- Zhang G, Manaca MN, McNamara-Smith M, Mayor A, Nhabomba A, Berthoud TK, *et al.* Interleukin-10 (IL-10) polymorphisms are associated with IL-10 production and clinical malaria in young children. *Infect Immun* 2012;80:2316-22.
- Lyke KE, Burges R, Cissoko Y, Sangare L, Dao M, Diarra I, *et al.* Serum levels of the proinflammatory cytokines interleukin-1 beta (IL-1beta), IL-6, IL-8, IL-10, tumor necrosis factor alpha, and IL-12(p70) in Malian children with severe *Plasmodium falciparum* malaria and matched uncomplicated malaria or healthy controls. *Infect Immun* 2004;72:5630-7.
- Borges QI, Fontes CJ, Damazo AS. Analysis of lymphocytes in patients with *Plasmodium vivax* malaria and its relation to the annexin-A1 and IL-10. *Malar J* 2013;12:455.
- Mayengue PI, Ndounga M, Malonga FV, Bitemo M, Ntoumi F. Genetic polymorphism of merozoite surface protein-1 and merozoite surface protein-2 in *Plasmodium falciparum* isolates from Brazzaville, Republic of Congo. *Malar J* 2011;10:276.
- Miller LH, Roberts T, Shahabuddin M, McCutchan TF. Analysis of sequence diversity in the *Plasmodium falciparum* merozoite surface protein-1 (MSP-1). *Mol Biochem Parasitol* 1993;59:1-14.
- Oyedemi SI, Awobode HO, Kun J. Limited Genetic diversity and low multiplicity of *Plasmodium falciparum* infections in children with severe malaria in Lafia, North-central Nigeria. *J Exp Clin Med* 2013; 5: 143-147.
- Kiwuwa MS, Ribacke U, Moll K, Byarugaba J, Lundblom K, Färnert A, *et al.* Genetic diversity of *Plasmodium falciparum* infections in mild and severe malaria of children from Kampala, Uganda. *Parasitol Res* 2013;112:1691-700.
- Amodu OK, Olaniyan SA, Omotade OO. Changes in *Plasmodium falciparum* population dynamics in two populations at different time periods in Ibadan, South West Nigeria. *Afr J Biomed Res* 2015; 18:17-22.
- Ojurongbe O, Ogungbamigbe TO, Fagbenro-Beyioku AF, Fendel R, Kremsner PG, Kun JF. Rapid detection of Pfort and Pfmrd1 mutations in *Plasmodium falciparum* isolates by FRET and *in vivo* response to chloroquine among children from Osogbo, Nigeria. *Malar J* 2007;6:41.
- Oyebola MK, Idowu ET, Olukosi YA, Iwalokun BA, Agomo CO, Ajibaye OO, *et al.* Genetic diversity and complexity of *Plasmodium falciparum* infections in Lagos, Nigeria. *Asian Pac J Trop Biomed* 2014;4 Suppl 1:S87-91.
- Barry AE, Schultz L, Senn N, Nale J, Kiniboro B, Siba PM, *et al.* High levels of genetic diversity of *Plasmodium falciparum* populations in Papua New Guinea despite variable infection prevalence. *Am J Trop Med Hyg* 2013;88:718-25.
- Mohammed H, Mindaye T, Belayneh M, Kassa M, Assefa A, Tadesse M, *et al.* Genetic diversity of *Plasmodium falciparum* isolates based on MSP-1 and MSP-2 genes from Kolla-Shele area, Arbaminch Zuria District, southwest Ethiopia. *Malaria journal*. 2015;1:1.
- Hartl DL, Clark AG. *Principles of Population Genetics*. Sunderland, MD: Sinauer Associates; 1997.
- Sanders PR, Gilson PR, Cantin GT, Greenbaum DC, Nebel T, Carucci DJ, *et al.* Distinct protein classes including novel merozoite surface antigens in raft-like membranes of *Plasmodium falciparum*. *J Biol Chem* 2005;280:40169-76.
- al-Yaman F, Genton B, Anders R, Taraika J, Ginny M, Mellor S, *et al.* Assessment of the role of the humoral response to *Plasmodium falciparum* MSP2 compared to RESA and SPf66 in protecting Papua New Guinean children from clinical malaria. *Parasite Immunol* 1995;17:493-501.
- Stanisic DI, Richards JS, McCallum FJ, Michon P, King CL, Schoepflin S, *et al.* Immunoglobulin G subclass-specific responses against *Plasmodium falciparum* merozoite antigens are associated with control of parasitemia and protection from symptomatic illness. *Infect Immun* 2009;77:1165-74.

To,  
The Editor

Covering Letter

**Submission of Manuscript for publication**

Dear Sir,

We intend to publish an article entitled

---

in your journal.

On behalf of all the contributors I will act and guarantor and will correspond with the journal from this point onward.

Prior presentation of the data reported in this manuscript:

Organisation

Place

Date

We have done sufficient work in the field to justify authorship for this manuscript.

We hereby transfer, assign, or otherwise convey all copyright ownership, including any and all rights incidental thereto, exclusively to the journal, in the event that such work is published by the journal.

Thank you,

Yours' sincerely,

Name of corresponding contributor

Signature



**Title of the manuscript:**

Title Page

**Type of manuscript:**

**Running title:**

**Contributors:**

	First name	Middle name initial	Last name	Highest academic degree	Names of departments and institutions (including city and state)	Email addresses
1						
2						
3						
4						
5						
6						

**Corresponding Author:**

Name:

Address:

Phone numbers:

Facsimile numbers:

E-mail address:

**Total number of pages:**

**Total number of tables:**

**Total number of figures:**

**Total number of supplementary files:**

**Word counts:** For abstract:

For the text:

**Acknowledgement:**

**Conflict of interest:**

**Financial Support:**

Contribution details (to be ticked marked as applicable):

Contributors' form

---

	Contributor 1	Contributor 2	Contributor 3	Contributor 4	Contributor 5	Contributor 6
Concepts						
Design						
Definition of intellectual content						
Literature search						
Clinical studies						
Experimental studies						
Data acquisition						
Data analysis						
Statistical analysis						
Manuscript preparation						
Manuscript editing						
Manuscript review						
Guarantor						